{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:16:52Z","timestamp":1790727412110,"version":"4.1.0"},"reference-count":35,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2008,10,8]],"date-time":"2008-10-08T00:00:00Z","timestamp":1223424000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Addiction"],"published-print":{"date-parts":[[2008,12]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:p><jats:bold>Aim\u2003<\/jats:bold>To compare the efficacy of topiramate with naltrexone in the treatment of alcohol dependence.<\/jats:p><jats:p><jats:bold>Design\u2003<\/jats:bold>The investigation was a double\u2010blind, placebo\u2010controlled, 12\u2010week study carried out at the University of S\u00e3o Paulo, Brazil.<\/jats:p><jats:p><jats:bold>Sample\u2003<\/jats:bold>A total of 155 patients, 18\u201360 years of age, with an International Classification of Diseases (ICD\u201010) diagnosis of alcohol dependence.<\/jats:p><jats:p><jats:bold>Methods\u2003<\/jats:bold>After a 1\u2010week detoxification period, patients were assigned randomly to receive topiramate (induction to 300\u2003mg\/day), naltrexone (50\u2003mg\/day) or placebo.<\/jats:p><jats:p><jats:bold>Measurements\u2003<\/jats:bold>Time to first relapse (consumption of &gt;60\u2003g ethyl alcohol), cumulative abstinence duration and weeks of heavy drinking.<\/jats:p><jats:p><jats:bold>Findings\u2003<\/jats:bold>In intention\u2010to\u2010treat analyses, topiramate was statistically superior to placebo on a number of measures including time to first relapse (7.8 versus 5.0 weeks), cumulative abstinence duration (8.2 versus 5.6 weeks), weeks of heavy drinking (3.4 versus 5.9) and percentage of subjects abstinent at 4 weeks (67.3 versus 42.6) and 8 weeks (61.5 versus 31.5), but not 12 weeks (46.2 versus 27.8). Results remained significant after controlling for Alcoholics Anonymous attendance, which was higher in topiramate than in other groups. There were no significant differences between naltrexone versus placebo or naltrexone versus topiramate groups, but naltrexone showed trends toward inferior outcomes when compared to topiramate.<\/jats:p><jats:p><jats:bold>Conclusions\u2003<\/jats:bold>The results of this study support the efficacy of topiramate in the relapse prevention of alcoholism. Suggestive evidence was also obtained for superiority of topiramate versus naltrexone, but this needs to be verified in future research with larger sample sizes.<\/jats:p>","DOI":"10.1111\/j.1360-0443.2008.02355.x","type":"journal-article","created":{"date-parts":[[2008,10,8]],"date-time":"2008-10-08T19:38:12Z","timestamp":1223494692000},"page":"2035-2044","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":119,"title":["Comparing topiramate with naltrexone in the treatment of alcohol dependence*"],"prefix":"10.1111","volume":"103","author":[{"given":"Danilo Antonio","family":"Baltieri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio Ruiz","family":"Dar\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip Leite","family":"Ribeiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arthur Guerra","family":"De Andrade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2008,11,6]]},"reference":[{"key":"e_1_2_6_2_2","volume-title":"Levantamento Domiciliar de Drogas Psicotr\u00f3picas no Brasil: Estudo Envolvendo as 107 Maiores Cidades do Pa\u00eds [Household Survey on Drug Abuse in Brazil: Study Involving the 107 Major Cities of the Country]","author":"Carlini E. A.","year":"2001"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2007.08.005"},{"key":"e_1_2_6_4_2","volume-title":"The Science of Addiction. From Neurobiology to Treatment","author":"Erickson C. K.","year":"2007"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1080\/09595230601036937"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.2165\/00023210-200418080-00002"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2006.02.001"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1358\/dot.1999.35.1.522947"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-4159.2005.03259.x"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1527-3458.2003.tb00260.x"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.2165\/00023210-200519060-00004"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)13370-3"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2004-815473"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.61.9.905"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.2006.01576.x"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.298.14.1641"},{"key":"e_1_2_6_17_2","first-page":"147","article-title":"The clinical pharmacology of naltrexone: pharmacology and pharmacodynamics","volume":"28","author":"Verebey K.","year":"1981","journal-title":"NIDA Res Monogr"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1590\/S1516-44462004000500011"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.2004.00763.x"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1177\/0269881107078308"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1093\/alcalc\/36.5.419"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.2006.01555.x"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.60.1.92"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1093\/alcalc\/agm136"},{"key":"e_1_2_6_25_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1530-0277.2008.00680.x","article-title":"Using topiramate or naltrexone for the treatment of alcohol\u2010dependent patients","volume":"32","author":"Florez G.","year":"2008","journal-title":"Alcohol Clin Exp Res"},{"key":"e_1_2_6_26_2","volume-title":"The ICD\u201010 Classification of Mental and Behavioural Disorders: Clinical Descriptions and Diagnostic Guidelines","author":"World Health Organization","year":"1992"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.1983.tb02484.x"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.2044-8341.1959.tb00467.x"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1530-0277.1995.tb01475.x"},{"issue":"1987","key":"e_1_2_6_30_2","first-page":"1","article-title":"The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross\u2010sectional study of side effects in neuroleptic\u2010treated patients","volume":"334","author":"Lingjaerde O.","journal-title":"Acta Psychiatr Scand"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005650-198601000-00007"},{"key":"e_1_2_6_32_2","volume-title":"Motivational Interviewing. Preparing People to Change Addictive Behavior","author":"Miller W. R.","year":"1991"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1360-0443.91.12s1.6.x"},{"key":"e_1_2_6_34_2","first-page":"236","article-title":"Topiramate as add\u2010on therapy in non\u2010respondent alcohol dependant patients: a 12 month follow\u2010up study","volume":"35","author":"Miranda J. J. F.","year":"2007","journal-title":"Actas Esp Psiquiatr"},{"key":"e_1_2_6_35_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200443120-00001"},{"key":"e_1_2_6_36_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.295.17.2003"}],"container-title":["Addiction"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1360-0443.2008.02355.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1360-0443.2008.02355.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T13:29:43Z","timestamp":1709299783000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1360-0443.2008.02355.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,11,6]]},"references-count":35,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2008,12]]}},"alternative-id":["10.1111\/j.1360-0443.2008.02355.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1360-0443.2008.02355.x","archive":["Portico"],"relation":{},"ISSN":["0965-2140","1360-0443"],"issn-type":[{"value":"0965-2140","type":"print"},{"value":"1360-0443","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,11,6]]},"assertion":[{"value":"2008-11-06","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}